Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADOX Trial: Apixaban for Prevention of Paradoxical Emboli
NCT02378623Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in paradoxical embolism (PDE) comparing Apixaban with Placebo (2 arms). Primary endpoint: Increase in number of new brain lesions detected on MRI >=3 mm in size at 2 years. Planned start May 2015; status: withdrawn.
02
Drugs
apixaban
03
Conditions
paradoxical embolism (PDE)
Beyond the preview
Go deeper on NCT02378623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378623.